ZHEJIANG HUAKANG PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.93 CNY | -1.20% |
|
+13.04% | +10.58% |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Capitalization 1 | 6,931 | 5,077 | 5,467 | - |
| Enterprise Value (EV) 1 | 6,931 | 5,077 | 5,467 | 5,467 |
| P/E ratio | 21.7 x | - | - | - |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | 1.82 x | 1.52 x | 1.28 x |
| EV / Revenue | - | 1.82 x | 1.52 x | 1.28 x |
| EV / EBITDA | - | 8.38 x | 8.42 x | 7.33 x |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Price to Book | - | 1.75 x | 1.71 x | 1.55 x |
| Nbr of stocks (in thousands) | 228,458 | 234,608 | 228,458 | - |
| Reference price 2 | 30.34 | 21.64 | 23.93 | 23.93 |
| Announcement Date | 3/23/23 | 4/18/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net sales 1 | - | 2,783 | 3,589 | 4,268 |
| EBITDA 1 | - | 605.9 | 649 | 746 |
| EBIT 1 | - | 427.1 | 488 | 566 |
| Operating Margin | - | 15.35% | 13.6% | 13.26% |
| Earnings before Tax (EBT) | - | - | - | - |
| Net income | 319.3 | - | - | - |
| Net margin | - | - | - | - |
| EPS | 1.400 | - | - | - |
| Free Cash Flow | - | - | - | - |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 3/23/23 | 4/18/24 | - | - |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Debt | - | - | - | - |
| Net Cash position | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow | - | - | - | - |
| ROE (net income / shareholders' equity) | - | 13.5% | 14% | 14.7% |
| ROA (Net income/ Total Assets) | - | - | 10.1% | 10.7% |
| Assets | - | - | - | - |
| Book Value Per Share 1 | - | 12.30 | 14.00 | 15.50 |
| Cash Flow per Share | - | - | - | - |
| Capex 2 | - | 690 | 400 | 300 |
| Capex / Sales | - | 24.78% | 11.15% | 7.03% |
| Announcement Date | 3/23/23 | 4/18/24 | - | - |
1CNY2CNY in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
23.93
CNY
Average target price
25
CNY
Spread / Average Target
+4.47%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +10.58% | 766M | |
| +2.37% | 29.94B | |
| +20.02% | 24.78B | |
| +6.21% | 11.15B | |
| +18.74% | 5.4B | |
| +20.42% | 4.57B | |
| -9.27% | 3.84B | |
| +2.35% | 3.38B | |
| +4.52% | 3.14B | |
| +29.28% | 2.88B |
- Stock Market
- Equities
- 605077 Stock
- Financials Zhejiang Huakang Pharmaceutical Co., Ltd.